4SC-202 provokes apoptosis activation in CRC cells, while caspase inhibitors (z-VAD-CHO and z-DVED-CHO) significantly alleviate 4SC-202-exerted cytotoxicity in CRC cells. Meanwhile, 4SC-202 induces dramatic G2-M arrest in CRC cells. Further studies show that AKT activation might be an important resistance factor of 4SC-202. 4SC-202-induced cytotoxicity is dramatically potentiated with serum starvation, AKT inhibition (by perifosine or MK-2206), or AKT1-shRNA knockdown in CRC cells. On the other hand, exogenous expression of constitutively active AKT1 (CA-AKT1) decreases the sensitivity by 4SC-202 in HT-29 cells. Notably, 4SC-202, at a low concentration, enhances oxaliplatin-induced in vitro anti-CRC activity[2]. 4SC-202 obviously reduces the proliferation of all epithelial and mesenchymal UC cell lines (IC50: 0.15-0.51 μM), inhibits clonogenic growth and induces caspase activity[1]. 4SC-202 treatment induces potent cytotoxic and proliferation-inhibitory activities against established HCC cell lines (HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. 4SC-202 induces apoptosis signal-regulating kinase 1 (ASK1) activation, causing it translocation to mitochondria and physical association with Cyp-D[3].

4SC-202 (i.g.) inhibits HT-29 xenograft growth in nude mice, and when combined with oxaliplatin, its activity is further strengthened[2].

1186222-89-8

C30H29N5O6S2

619.71

4SC-202 tosylate;4SC-202

DMSO:50 mg/mL
H2O:Insoluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years